Chronic Pain as a Disease: Mechanisms and Future Treatments

Beyond TMS, advanced neuromodulation includes deep brain stimulation (DBS) for Parkinson's disease, vagus nerve stimulation (VNS) for epilepsy and depression, and transcranial direct current stimulation (tDCS) for cognitive enhancement. tDCS devices, smaller than smartphones, can be used at home but raise ethical concerns about cognitive enhancement in competitive environments. Emerging technologies include focused ultrasound for Alzheimer's disease (removing amyloid plaques) and photobiomodulation (Brazil's first approval for anxiety, depression, and insomnia).

Optogenetics and chemogenetics represent the most advanced neuromodulation techniques, using a lock and key mechanism. These methods require genetic modification to make neurons sensitive to light or chemical substances. Once prepared, researchers can precisely activate or inhibit specific neural circuits. Research has demonstrated the ability to create artificial memories in animals by activating specific neural circuits in contexts where nothing happened. Understanding which neural circuits underlie specific behaviors allows researchers to manipulate those circuits to influence emotions, thoughts, and actions.

Advanced neuromodulation applications extend beyond pain to address complex neurological conditions. Complex Regional Pain Syndrome (CRPS) represents a severe condition where pain severity exceeds original injury severity, potentially causing bone destruction; spinal cord stimulation has proven more effective than conservative treatment alone. Sacral nerve stimulation restores function in pelvic floor disorders including fecal and urinary incontinence, with some patients achieving complete recovery after years of symptoms. Vagus nerve stimulation, primarily used for epilepsy, shows promise for depression, anxiety, asthma, and brain injury rehabilitation. Deep brain stimulation has revolutionized treatment for Parkinson's disease and dystonia, producing dramatic visible improvements—tremors stop, abnormal postures correct, and dyskinesias improve. Neuromodulation systems consist of electrodes with contact surfaces, leads connecting to generators implanted under the skin, and remote controls for patient adjustment. For peripheral nerve stimulation, leads are tunneled under the skin to target nerves. For sacral nerve stimulation, leads are inserted through sacral foramina to target the third sacral nerve root.

For patients unresponsive to conventional treatments, advanced neuromodulation therapies offer hope. Deep brain stimulation implants electrodes in the brain's reward system to disrupt abnormal neural activity associated with depression. Electroconvulsive therapy uses controlled electrical stimulation to promote neuroplasticity and neurotransmitter release. Both approaches achieve positive outcomes in approximately 75-80% of treatment-resistant cases. These interventions represent the frontier of psychiatric treatment, offering hope where traditional approaches have failed.

This section examines newer neuromodulation approaches: Vagus Nerve Stimulation (VNS), Trigeminal Nerve Stimulation (eTNS), and Neurofeedback. VNS requires surgical implantation and shows effects after 6-9 months. eTNS received FDA approval in 2019 for ADHD in children 7-12, delivering stimulation during sleep. Neurofeedback uses real-time brainwave monitoring with visual/audio feedback to teach self-regulation. While non-invasive, these alternatives face challenges including high costs, lack of standardization, and limited insurance coverage. Each approach represents different balances between invasiveness, efficacy timeline, and accessibility in treating mental health conditions.

The biopsychosocial model of pain considers that pain is influenced by biological, psychological, and social factors. The video explains that emotional and psychological states can significantly affect pain perception and treatment outcomes. Psychological factors can contribute to the development of chronic pain conditions, and negative psychological states can negatively affect treatment outcomes. The nocebo effect demonstrates how negative expectations or suggestions can worsen pain symptoms. Effective pain management must address all three dimensions rather than focusing solely on physical symptoms.

Pain sits at the intersection of biological factors (tissue health, genetics), psychological factors (thoughts, beliefs, mood), and social factors (relationships, culture, access to care). Both Dims and Sims can be found across all three domains.

The biopsychosocial model explains that pain perception involves biological (tissue damage), psychological (brain interpretation), and social (environmental context) components. Anxiety and negative social environments increase pain perception, while positive coaching and external focus techniques reduce it. This model supports early movement after injury, as immobilization and fear-based messaging can perpetuate chronic pain states. The eight-week isometric rehabilitation course is essential—many patients prematurely discontinue treatment after feeling better, risking recurrence.

The biomedical model, which previously dominated healthcare, held that tissue damage directly causes pain and dysfunction. This has been replaced by the biopsychosocial model, which recognizes that pain experience results from biological factors (tissue damage), psychological factors (beliefs, expectations, emotions), and social factors (cultural influences, family history) working together. For example, low back pain from training typically has minimal biological input but significant psychological and social components. A person with the same biological condition may or may not experience pain based on their mental model and social learning.

Pain extends beyond physical tissue damage through the biopsychosocial model: (1) Biological—tissue damage, inflammation, and injury; (2) Psychological—fear avoidance, anxiety, depression, and rumination on pain; (3) Social—cultural upbringing, work environment, and support system. Fear avoidance of movements tells the nervous system that certain positions should be avoided, which increases pain signals. Anxiety and depression activate the stress response, tightening the body and amplifying pain signals. These factors exist on a spectrum—small amounts of anxiety or racing thoughts can influence pain. Simply doing exercises without addressing psychological factors will not resolve pain.

A therapeutic is defined as a treatment, therapy, or drug used to treat diseases. Traditional chemotherapies cause adverse side effects because they affect both cancer cells and normal healthy cells. Targeted therapeutics represent a newer class of drugs that only affect target cells, eliminating effects on normal cells and reducing side effects. Examples include erlotinib (Tarceva) for lung cancer targeting EGFR tyrosine kinase, pembrolizumab (Keytruda) for cancers targeting PD-1 pathway, and rituximab (Rituxan) for autoimmune diseases targeting CD20 on B-cells. The therapeutic discovery process is time-consuming and costly, estimated to take 10-15 years and cost $500 million to several billion dollars to bring one therapy to market.

This section covers poisoning management and novel drug developments. Anti-HIV drug adverse effects include: zidovudine causing bone marrow suppression and lactic acidosis, stavudine causing peripheral neuropathy and lipodystrophy, didanosine causing pancreatitis, efavirenz causing psychiatric symptoms, and nevirapine causing hepatotoxicity. Critical antidotes include: beta blockers - glucagon; organophosphates - atropine; benzodiazepines - flumazenil; cyanide - hydroxocobalamin; methanol - fomepizole (ethanol alternative); iron - deferoxamine; acetaminophen - NAC; heparin - protamine sulfate; warfarin - vitamin K. Emerging therapies include: ivacaftor (CF potentiator), sulopenem (carbapenem for UTI), olesoxime (antisense for chylomicronemia), fostamatinib (endothelin antagonist for IgA nephropathy), japtivir (topoisomerase inhibitor for UTI), sunitinib (sodium channel blocker for pain), metoprolol (ultrashort beta blocker for SVT), xanomeline/tropium (schizophrenia treatment), and resmetirom (thyroid receptor modulator for NASH).

Advanced pharmacology encompasses: PCSK9 inhibitors (evolocumab, alirocumab) reduce LDL by blocking receptor degradation; HER2 inhibitors (trastuzumab, pertuzumab, trastuzumab emtansine) for HER2-positive breast cancer; EGFR inhibitors (cetuximab, panitumumab, erlotinib) for EGFR-mutant cancers; Cannabinoids (dronabinol, nabilone) for Lennox-Gastaut syndrome; Teriparatide (recombinant PTH analog) for osteoporosis with osteonecrosis risk; Fluoroquinolones cause skin pigmentation and tendinitis; Metformin causes lactic acidosis and vitamin B12 deficiency.

Current chemotherapy fails for metastatic cancer because it lacks selectivity, attacking both tumors and normal tissues. This toxicity limits treatment duration and effectiveness. The solution requires targeted therapeutics that selectively destroy cancer cells while sparing healthy tissue. Oncolytic viruses represent such an approach—they can be administered systemically, find tumors throughout the body, replicate within them, and destroy them. Successful models demonstrate complete tumor clearance without normal tissue damage, establishing the foundational concept for this therapeutic strategy.

Clinical pharmacology is the translational discipline focused on understanding drug actions in humans, spanning drug discovery, development, utilization, and regulation, with key areas including pharmacokinetics (how the body handles drugs), pharmacodynamics (drug effects on the body), variability in drug response, and adverse drug reactions; this field emerged from pioneers like Harry Gold and Walter Modell who introduced the double-blind clinical trial design and founded the journal Clinical Pharmacology and Therapeutics in 1960, and continues to evolve through drug repurposing strategies that leverage existing drug knowledge to find new therapeutic applications more efficiently than developing entirely new compounds.